Episode 124 – A Vital Project – Pursuing Antibody Science in a Pandemic

Pioneering the development of human monoclonal antibodies as potential treatments for viral diseases, in 2019 the Crowe Lab did a simulated pandemic outbreak and developed a record breaking rapid antibody discovery platform. Dr. James E. Crowe, Director of the Vanderbilt Vaccine Center shares how in 2020, as they were getting ready to do another simulation, right in the middle of their preparations COVID happened. Hear the fascinating story of how his team pivoted to launch a project with no reagents, no information, and no samples.  Table of Contents 01:37 … Meet James03:12 … What is an Antibody?04:17 … Monoclonal Antibodies06:44 … The Human Immunome Project09:25 … Secrets in our Bloodstream12:02 … COVID Response15:55 … Getting the Team to Pivot20:02 … Concerning Vaccine Hesitancy26:25 … Decision Analysis and Risks28:06 … Deciding on Intellectual Property34:02 … Formal Project Management in the Lab36:35 … After Action Reviews38:01 … Project Management Processes and Practices42:45 … Get in Touch with James43:50 … Closing JAMES CROWE: I like the complexity of it, and I like working with project managers because they like seeing the complexity.  And the bottom line is getting things done in a complex environment.  That’s getting stuff out the other end and not being discouraged by that, but enjoying the complexity. WENDY GROUNDS:  Welcome to Manage This, the podcast for project managers by project managers.  I’m Wendy Grounds; and, as always, here in the studio with me is Bill Yates. Listeners remember if you’re claiming PDUs for our podcast, as well as for our courses, check out our website. Our PDU claim page has been updated with the new instructions.  We are so glad you’re joining us today.  We have a special guest.  This is Dr. James Crowe, and he’s a physician scientist at the Vanderbilt University Medical Center.  He’s the director of the Vanderbilt Vaccine Center and the Ann Scott Carell Chair.  He’s a Professor of Pediatrics and Pathology, Microbiology and Immunology. BILL YATES:  Dr. Crowe has pioneered development of human monoclonal antibodies as potential treatments for viral diseases.  He’s going to describe to us what that means.  I think we’ve all heard about antibodies lately.  But he can describe it from a science perspective.  And they’d done a lot of work on antibodies prior to the COVID pandemic.  But when the pandemic hit, his team pivoted, and we’ll talk with him about that.  In fact, the Crowe team won an award in December 2020.  They were recognized for their work on COVID antibody research, and that’s a fantastic award that recognizes the achievement that they’ve had in that field. WENDY GROUNDS:  Yes.  So he gives some great project management advice in this podcast.  It’s really interesting to hear his perspective.  And also something we ask James is why we’re still debating the social good and the necessity of vaccines.  And he touches on that, as well.  So let’s talk to James.  Hi, Dr. Crowe.  Thank you so much for joining us today. Meet James JAMES CROWE:  Yeah, thanks for having me. WENDY GROUNDS:  We’re just so excited to talk with you today, to clarify some issues about vaccines and about immunization.  And I think you’re just the right person to talk to.  But I want to just go back a little bit and find out what is your mission as a scientist in the vaccine area?  How did you get started in this?  And what really is your goal? JAMES CROWE:  Well, I trained originally as a pediatrician, and ultimately worked in various places around the world.  I traveled in Papua New Guinea and Sub-Saharan Africa and various exotic places, thinking that I might spend my life trying to make the world a better a better place for children who are in challenging situations.  And when you’re there, you see infectious diseases as a big part of the challenge.  Ultimately I trained as an infectious disease specialist to try to work on prevention of disease, infectious diseases,